Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: fast dissolve tablet therapeutics - Samyang

Next Previous
Drug Profile

Research programme: fast dissolve tablet therapeutics - Samyang

Alternative Names: Methylphenidate fast disolve tablet - Samyang; Orally disintegrating tablet therapeutics - Samyang; Risperidone fast disolve tablet - Samyang; Tacrolimus fast disolve tablet - Samyang

Latest Information Update: 10 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Samyang Biopharmaceuticals Corporation; Samyang Group
  • Developer Samyang Biopharmaceuticals Corporation
  • Class Isoxazoles; Lactones; Macrolides; Phenylacetates; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Calcineurin inhibitors; Cytokine inhibitors; Dopamine D2 receptor antagonists; Dopamine release stimulants; Immunosuppressants; Serotonin 5-HT2A receptor antagonists; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Attention-deficit hyperactivity disorder; Schizophrenia; Transplant rejection

Most Recent Events

  • 10 Apr 2025 Discontinued - Preclinical for Attention-deficit hyperactivity disorder in South Korea (PO)
  • 10 Apr 2025 Discontinued - Preclinical for Schizophrenia in South Korea (PO)
  • 10 Apr 2025 Discontinued - Preclinical for Transplant rejection in South Korea (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top